CIRB Studies

Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.

To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.

Displaying 31 - 40 of 842
Study Number Lead Group Study Title CIRB Study Status
NWU2016-08-02 CLO-Northwestern University A Phase I Single-Arm, Multicenter Pilot Study Aimed at Validating Gamma-OHPdG as a Biomarker and Testing the Effects of Polyphenon E® on its Levels in Patients with Cirrhosis Cancer Prevention and Control CIRB Available to Open
9846 ETCTN Patient-Derived Models Tissue Procurement Protocol For The National Cancer Institute (NCI) Adult CIRB - Early Phase Emphasis Available to Open
10183 ETCTN A Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma Adult CIRB - Early Phase Emphasis Available to Open
10346 ETCTN Pilot Study of DS-8201a Pharmacodynamics in Patients with HER2-expressing Advanced Solid Tumors Adult CIRB - Early Phase Emphasis Available to Open
RTOG-0232 RTOG A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma Adult CIRB - Late Phase Emphasis Available to Open
CALGB-10603 CALGB A Phase III Randomized; Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML) Adult CIRB - Late Phase Emphasis Available to Open
S1607 SWOG A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients with Advanced Melanoma who have Progressed on ANTI-PD1/L1 Based Therapy Adult CIRB - Late Phase Emphasis Available to Open
EAE161 ECOG-ACRIN Perfusion CT to Predict Progression-free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma Adult CIRB - Late Phase Emphasis Available to Open
AREN0532 COG Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor: A Groupwide Phase III Study Pediatric CIRB Available to Open
ADVL1515 COG A Phase 1 Study of LY2606368, (prexasertib mesylate monohydrate) (IND# 132233), a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors Pediatric CIRB Available to Open
Displaying 31 - 40 of 842